Video

Dr. Dason on selecting neoadjuvant or adjuvant therapy for patients with UTUC

Author(s):

Urology Times staff

“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.

In this video, Shawn Dason, MD, FRCSC, discusses the factors that urologists should consider when counseling patients with upper tract urothelial carcinoma about neoadjuvant and adjuvant treatment options. These insights stem from a study that was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman talking with doctor | Image Credit: © LuneVA/peopleimages.com - stock.adobe.com
Timothy D. Lyon, MD, answers a question during a video interview
Amy E. Krambeck, MD, answers a question during a Zoom video interview
Related Content
US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
January 29th 2025

UTUC roundtable discussions highlight guidelines, patient cases

Urology Times staff
Two recent roundtable discussions focused on the challenges and evolving treatment strategies in upper tract urothelial carcinoma.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Anktiva under review in EU for BCG-unresponsive NMIBC with CIS
January 27th 2025

Anktiva under review in EU for BCG-unresponsive NMIBC with CIS

Hannah Clarke
If approved, the marketing authorization application would be valid in all 27 European Union member states as well as in Iceland, Liechtenstein, and Norway.
UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma
January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke
"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.
© 2025 MJH Life Sciences

All rights reserved.